Characteristics of participants in cohort 2
. | IL-2 group (n = 29) . | . | Control group (n = 23) . | . | ||
|---|---|---|---|---|---|---|
. | Month 0 . | Month 12 . | Month 0 . | Month 12 . | ||
| No. CD4 cells/μL (range) | 416 (225-753) | 713* (204-2862) | 378 (206-926) | 349 (56-958) | ||
| No. CD8 cells/μL (range) | 973 (184-1786) | 856 (200-2426) | 866 (488-2127) | 844 (329-1661) | ||
| No. HIV-RNA log copies/mL | 3.55 (1.69-4.84) | 3.51 (1.69-4.68) | 3.74 (1.73-4.98) | 3.73 (2.29-5.12) | ||
. | IL-2 group (n = 29) . | . | Control group (n = 23) . | . | ||
|---|---|---|---|---|---|---|
. | Month 0 . | Month 12 . | Month 0 . | Month 12 . | ||
| No. CD4 cells/μL (range) | 416 (225-753) | 713* (204-2862) | 378 (206-926) | 349 (56-958) | ||
| No. CD8 cells/μL (range) | 973 (184-1786) | 856 (200-2426) | 866 (488-2127) | 844 (329-1661) | ||
| No. HIV-RNA log copies/mL | 3.55 (1.69-4.84) | 3.51 (1.69-4.68) | 3.74 (1.73-4.98) | 3.73 (2.29-5.12) | ||
Median values are given, with range in parentheses. *P < .001 compared to month 0; P = .002 compared to control group at month 12.